Fidelity Investments
RNTX

Fidelity Investments’s Rein Therapeutics RNTX Stock Holding History

Fidelity Investments’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-233
Closed -$825 – 5862
2024
Q3 		$825 Hold
233
– – ﹤0.01% 4930
2024
Q2 		$645 Hold
233
– – ﹤0.01% 4844
2024
Q1 		$1.51K Buy
233
+183
+366% +$876 ﹤0.01% 4736
2023
Q4 		$152 Buy
+50
New +$97 ﹤0.01% 4904

Other funds holding RNTX

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $687M AUM 21.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Fidelity Investments's RNTX Position: Q4 2024 in Review

Fidelity Investments sold out of Rein Therapeutics (RNTX) in Q4 2024, closing a stake of 233 shares — an estimated $825 sold.

Fidelity Investments first reported a position in RNTX in Q4 2023 and held it in 4 quarters. The position peaked at $1.51K in Q1 2024. 31 funds tracked by Wall St. Rank hold RNTX as of Q4 2024.

  • Fidelity Investments reported no remaining Rein Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Fidelity Investments sold 233 Rein Therapeutics shares in Q4 2024, an estimated $825.
  • Fidelity Investments first reported a position in Rein Therapeutics in Q4 2023 and held it in 4 quarters.
  • Fidelity Investments's Rein Therapeutics position peaked at $1.51K in Q1 2024.
  • 31 funds tracked by Wall St. Rank held Rein Therapeutics as of Q4 2024.

Based on Fidelity Investments's 13F filing for Q4 2024, filed 13 Feb 2025.